Literature DB >> 32215933

Dexmedetomidine in the prevention of postoperative delirium in elderly patients following non-cardiac surgery: A systematic review and meta-analysis.

Qi-Hong Shen1, Hui-Fang Li2, Xu-Yan Zhou1, Xiao-Zhong Yuan1.   

Abstract

The efficacy of dexmedetomidine in the prevention of postoperative delirium (POD) remains ambiguous, however, it has been used to reduce the incidence of delirium in elderly patients. Here, we conducted a meta-analysis study for assessing the effects of dexmedetomidine on POD among elderly patients following non-cardiac surgery. A systematic literature search was performed against the PubMed, EMBASE, Cochrane Library, and Web of Science databases, and all relevant literature published till November 30, 2019, were considered. Our analysis included 16 randomised controlled trials conducted with 4534 patients for exploring the effects of dexmedetomidine on POD in elderly patients following non-cardiac surgery. It was observed that the overall incidence of POD was significantly lower in the dexmedetomidine group than in the control group (risk ratio [RR] 0.51, 95% confidence interval [CI] 0.43-0.61, P < .01). Similar results were obtained from subgroup analysis upon comparison of the placebo (RR 0.52, 95% CI 0.41-0.66, P < .01, moderate quality of evidence), propofol-treated (RR 0.55, 95% CI 0.38-0.78, P < .01, low quality of evidence), and midazolam-treated (RR 0.38, 95% CI 0.20-0.71, P < .01, low quality of evidence) groups. Trial sequential analysis revealed that the cumulative z-value superseded the monitoring boundary and reached the required information size. However, patients who received dexmedetomidine had a higher incidence of bradycardia and hypotension. In conclusion, the meta-analysis revealed that dexmedetomidine appears to decrease the risk of POD in elderly patients following non-cardiac surgery. However, as some of the studies were heterogeneous and of low quality, high-quality trials are necessary for drawing more definitive conclusions.
© 2020 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  dexmedetomidine; non-cardiac surgery; postoperative delirium

Year:  2020        PMID: 32215933     DOI: 10.1111/1440-1681.13312

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  5 in total

1.  Dexmedetomidine reduces the incidence of postoperative delirium after cardiac surgery: a meta-analysis of randomized controlled trials.

Authors:  Peng Li; Lu-Xi Li; Zhen-Zhen Zhao; Jian Xie; Cheng-Long Zhu; Xiao-Ming Deng; Jia-Feng Wang
Journal:  BMC Anesthesiol       Date:  2021-05-18       Impact factor: 2.217

2.  Dexmedetomidine for the prevention of postoperative delirium in patients after intracranial operation for brain tumours (DEPOD study): a study protocol and statistical plan for a multicentre randomised controlled trial.

Authors:  Xuan He; Kun-Ming Cheng; Linlin Zhang; Hongqiu Gu; Xin Qu; Yuan Xu; Penglin Ma; Jian-Xin Zhou
Journal:  BMJ Open       Date:  2020-11-23       Impact factor: 2.692

3.  Feasibility of low-dose dexmedetomidine for prevention of postoperative delirium after intracranial operations: a pilot randomized controlled trial.

Authors:  Xuan He; Kun-Ming Cheng; Yu-Qing Duan; Shan-Shan Xu; Hao-Ran Gao; Ming-Yue Miao; Hong-Liang Li; Kai Chen; Yan-Lin Yang; Linlin Zhang; Hong-Qiu Gu; Jian-Xin Zhou
Journal:  BMC Neurol       Date:  2021-12-04       Impact factor: 2.474

Review 4.  Evidence-Based Guideline on Management of Postoperative Delirium in Older People for Low Resource Setting: Systematic Review Article.

Authors:  Addisu Mossie; Teshome Regasa; Derartu Neme; Zemedu Awoke; Abebayehu Zemedkun; Seyoum Hailu
Journal:  Int J Gen Med       Date:  2022-04-14

5.  Dexmedetomidine effect on delirium in elderly patients undergoing general anesthesia: A protocol for systematic review and meta-analysis.

Authors:  Youran Wang; Xinyi Bu; Na Zhao; Shuxia Wang; Xiaoliang Wang; Yali Ge; Honggang Yi
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.